Cargando…
Population pharmacokinetics and pharmacodynamics of cysteamine in nephropathic cystinosis patients
BACKGROUND: Nephropathic cystinosis is an autosomal recessive disorder resulting in an impaired transport of cystine trough the lysosomal membrane causing an accumulation of free cystine in lysosomes. The only specific treatment for nephropathic cystinosis is cysteamine bitartrate. This study was ai...
Autores principales: | Bouazza, Naïm, Tréluyer, Jean-Marc, Ottolenghi, Chris, Urien, Saik, Deschenes, Georges, Ricquier, Daniel, Niaudet, Patrick, Chadefaux-Vekemans, Bernadette |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3257201/ https://www.ncbi.nlm.nih.gov/pubmed/22195601 http://dx.doi.org/10.1186/1750-1172-6-86 |
Ejemplares similares
-
A comparison of immediate release and delayed release cysteamine in 17 patients with nephropathic cystinosis
por: van Stein, Christina, et al.
Publicado: (2021) -
Quality of Life is Improved and Kidney Function Preserved in Patients with Nephropathic Cystinosis Treated for 2 Years with Delayed-Release Cysteamine Bitartrate
por: Langman, Craig B., et al.
Publicado: (2014) -
Long-term clinical benefits of delayed-release cysteamine bitartrate capsules in patients with nephropathic cystinosis (response to “A comparison of immediate release and delayed release cysteamine in 17 patients with nephropathic cystinosis”)
por: Langman, Craig B.
Publicado: (2023) -
Response to Cysteamine in Osteoclasts Obtained from Patients with Nephropathic Cystinosis: A Genotype/Phenotype Correlation
por: Quinaux, Thomas, et al.
Publicado: (2021) -
Enteric-Coated Cysteamine Bitartrate in Cystinosis Patients
por: Klank, Sabrina, et al.
Publicado: (2023)